Abstract
The sphingolipids ceramide, sphingosine, and sphingosine 1-phosphate (S1P) regulate cell signaling, proliferation, apoptosis, and autophagy. Sphingosine kinase-1 and -2 (SK1 and SK2) phosphorylate sphingosine to form S1P, shifting the balanced activity of these lipids toward cell proliferation. We have previously reported that pharmacological inhibition of SK activity delays tumor growth in vivo. The present studies demonstrate that the SK2-selective inhibitor 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) induces nonapoptotic cell death that is preceded by microtubule-associated protein light chain 3 cleavage, morphological changes in lysosomes, formation of autophagosomes, and increases in acidic vesicles in A-498 kidney carcinoma cells. ABC294640 caused similar autophagic responses in PC-3 prostate and MDA-MB-231 breast adenocarcinoma cells. Simultaneous exposure of A-498 cells to ABC294640 and 3-methyladenine, an inhibitor of autophagy, switched the mechanism of toxicity to apoptosis, but decreased the potency of the SK2 inhibitor, indicating that autophagy is a major mechanism for tumor cell killing by this compound. Induction of the unfolded protein response by the proteasome inhibitor N-(benzyloxycarbonyl)leucinylleucinylleucinal Z-Leu-Leu-Leu-al (MG-132) or the heat shock protein 90 inhibitor geldanamycin synergistically increased the cytotoxicity of ABC294640 in vitro. In severe combined immunodeficient mice bearing A-498 xenografts, daily administration of ABC294640 delayed tumor growth and elevated autophagy markers, but did not increase terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive cells in the tumors. These data suggest that ABC294640 promotes tumor cell autophagy, which ultimately results in nonapoptotic cell death and a delay of tumor growth in vivo. Consequently, ABC294640 may effectively complement anticancer drugs that induce tumor cell apoptosis.
Footnotes
This work was supported by the National Institute of Healths [Grant R01-CA122226] (to C.D.S.). The Imaging Core of the Hollings Cancer Center is supported by National Institutes of Health [Grant CA138313-01] (to Dr. Andrew Kraft).
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.109.163337.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- SK1
- sphingosine kinase-1
- SK2
- sphingosine kinase-2
- 3-MeA
- 3-methyladenine
- ABC294640
- 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
- DMS
- dimethylsphingosine; LC3; tubulin-associated protein light chain 3
- PI
- propidium iodide
- shRNA
- short-hairpin RNA
- SKI-2
- 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol
- S1P
- sphingosine 1-phosphate
- SRB
- sulforhodamine B
- TUNEL
- terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling
- MG-132
- N-(benzyloxycarbonyl)leucinylleucinylleucinal Z-Leu-Leu-Leu-al
- SCID
- severe combined immunodeficient
- mTOR
- mammalian target of rapamycin
- MEK
- mitogen-activated protein kinase
- ERK
- extracellular signal-regulated kinase
- PAGE
- polyacrylamide gel electrophoresis
- PBS
- phosphate-buffered saline
- PCR
- polymerase chain reaction
- MAPK
- mitogen-activated protein kinase
- PI3K
- phosphatidylinositol 3-kinase
- CI
- combination index.
- Received November 3, 2009.
- Accepted February 22, 2010.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|